Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights
As patients struggle with treatment burdens and suboptimal outcomes, new pipeline therapies spark hope for meaningful transformation across nAMD, DME, GA, and UME. Exton, PA, August 28, 2025 — In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S. ophthalmologists, including retina specialists, sheds light […]
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. Exton, PA, August 28, 2025 – The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a vast patient population and significant […]
Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
Breakthrough therapies targeting APOL1 and reducing steroid dependence could redefine treatment standards for FSGS EXTON, PA, August 21, 2025 —The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection point. New data from Spherix Global Insights’ seventh annual Market Dynamix™: FSGS (US) study highlight both […]
Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas
EXTON, PA, August 19, 2025 – Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical stakeholders with critical, forward-looking intelligence into payer priorities, strategies, and evolving access dynamics across a broad range of therapeutic categories. The report will be delivered to subscribed clients at the end […]
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights. Exton, PA, August 6, 2025 – The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace […]
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, August 6, 2025 — According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the […]
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights
Hematologists are poised to jump on new market entrants once available, as high unmet need and frustration with current treatment standards persist in w-AIHA. EXTON, PA, July 29, 2025— According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune hemolytic anemia (w-AIHA) continue to face clinical complexity, […]
A New PsA Drug Brings Relief, But Getting an Rx Is a Challenge
Doctors, patients struggle with new drug coverage. The recent approval of a new drug to treat psoriatic arthritis (PsA) was a welcome development for people living with this painful condition and the doctors who treat them. But those enthusiastic to try Bimzelx (bimekizumab) have run into a common problem associated with many types of new […]
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Exton, PA, July 17, 2025 – The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, […]
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as well as continued use of Alexion’s Soliris and Ultomiris and Apellis’ Empaveli. EXTON, PA, July 17, 2025 – In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global Insights explores the nuanced dynamics […]
